FDA.reportPublic FDA data

FDA label 7f6517b2-e33f-ab24-e053-2991aa0a3804

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
7f6517b2-e33e-ab24-e053-2991aa0a3804
SPL ID
7f6517b2-e33f-ab24-e053-2991aa0a3804
Version
1
Effective date
2019-01-14
Source export date
2026-10-30
Source partition
11
Source file
https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-30/9abf0f8b126f8aad070e21ea702bfb5e39ce670b16ae57dd52e8877705d1bf5d/drug-label-0011-of-0014.json.zip
Source manifest SHA-256
b11f1f6b476c7417db937215bf14307ef1a0b69465b42b411ad52f42ae36ead3
Import run
20261102T182004Z
Imported at
2026-11-02 19:34:06

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Do not administer this product to patients who are Galactose intolerance, Lapp lactase deficiency, or Glucose-glalactose malabsorption. BIOVITA should be used carefully with patients under medical conditions. Follow the dosage recommendations. If symptoms do not improve after two weeks to one month, it is recommended to consult with physician or pharmacist. Consult with a doctor or pharmacist for baby who is under 3 months that is administered with this product. Keep in a dry and cool place without direct sunlight.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.